L. M. Hutt-fletcher, Epstein-Barr virus replicating in epithelial cells, Proc Natl Acad Sci U S A, vol.111, p.25385596, 2014.

L. S. Young and A. B. Rickinson, Epstein-Barr virus: 40 years on, Nat Rev Cancer, vol.4, p.15510157, 2004.

A. H. Draborg, K. Duus, and G. Houen, Epstein-Barr virus in systemic autoimmune diseases, Clin Dev Immunol, p.24062777, 2013.

M. A. Epstein and B. G. Achong, The EB virus, Annu Rev Microbiol, vol.27, p.4356531, 1973.

J. I. Cohen, Epstein-barr virus vaccines, Clin Transl Immunology, vol.4, p.25671130, 2015.

E. M. Sokal, K. Hoppenbrouwers, C. Vandermeulen, M. Moutschen, and P. Leonard, Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults, J Infect Dis, vol.196, p.18190254, 2007.

M. Bencun, O. Klinke, A. Hotz-wagenblatt, K. S. Tsai, and M. H. , Translational profiling of B cells infected with the Epstein-Barr virus reveals 5' leader ribosome recruitment through upstream open reading frames, Nucleic Acids Res, vol.46, p.29529302, 2018.

E. Murphy, I. Rigoutsos, T. Shibuya, and T. E. Shenk, Reevaluation of human cytomegalovirus coding potential, Proc Natl Acad Sci U S A, vol.100, p.14593199, 2003.

C. Arias, B. Weisburd, N. Stern-ginossar, A. Mercier, and A. S. Madrid, KSHV 2.0: a comprehensive annotation of the Kaposi's sarcoma-associated herpesvirus genome using next-generation sequencing reveals novel genomic and functional features, PLoS Pathog, vol.10, p.24453964, 2014.

G. S. Taylor, H. M. Long, J. M. Brooks, A. B. Rickinson, and A. D. Hislop, The immunology of Epstein-Barr virus-induced disease, Annu Rev Immunol, vol.33, p.25706097, 2015.

S. Y. Gu, T. M. Huang, L. Ruan, Y. H. Miao, and H. Lu, First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen, Dev Biol Stand, vol.84, p.7796951, 1995.

M. Kanekiyo, W. Bu, M. G. Joyce, G. Meng, and J. R. Whittle, Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site, Cell, vol.162, p.26279189, 2015.

S. L. Elliott, A. Suhrbier, J. J. Miles, G. Lawrence, and S. J. Pye, Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis, J Virol, vol.82, p.18032491, 2008.

S. Pavlova, R. Feederle, K. Gartner, W. Fuchs, and H. Granzow, An Epstein-Barr virus mutant produces immunogenic defective particles devoid of viral DNA, J Virol, vol.87, p.23236073, 2013.

E. Johannsen, M. Luftig, M. R. Chase, S. Weicksel, and E. Cahir-mcfarland, Proteins of purified Epstein-Barr virus, Proc Natl Acad Sci U S A, vol.101, p.15534216, 2004.

H. M. Long, T. A. Haigh, N. H. Gudgeon, A. M. Leen, and C. W. Tsang, CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines, J Virol, vol.79, p.15795275, 2005.

D. Adhikary, U. Behrends, H. Boerschmann, A. Pfunder, and S. Burdach, Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy, PLoS One, vol.2, p.17611619, 2007.

X. Yu, M. Ilecka, E. J. Bartlett, V. Schneidt, and R. Bhat, Antigen-armed antibodies targeting B lymphoma cells effectively activate antigen-specific CD4+ T cells, Blood, vol.125, p.25568348, 2015.

G. J. Hoffman, S. G. Lazarowitz, and S. D. Hayward, Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen, Proc Natl Acad Sci, vol.77, p.6248876, 1980.

B. Neuhierl, R. Feederle, D. Adhikary, B. Hub, and K. Geletneky, Primary B-cell infection with a deltaBALF4 Epstein-Barr virus comes to a halt in the endosomal compartment yet still elicits a potent CD4-positive cytotoxic T-cell response, J Virol, vol.83, p.19244320, 2009.

A. Shumilov, M. H. Tsai, Y. T. Schlosser, A. S. Kratz, and K. Bernhardt, Epstein-Barr virus particles induce centrosome amplification and chromosomal instability, Nat Commun, vol.8, p.28186092, 2017.

S. A. Calarota, A. Chiesa, P. Zelini, G. Comolli, and L. Minoli, Detection of Epstein-Barr virus-specific memory CD4+ T cells using a peptide-based cultured enzyme-linked immunospot assay, Immunology, vol.139, p.23560877, 2013.

D. Adhikary, U. Behrends, R. Feederle, H. J. Delecluse, and J. Mautner, Standardized and highly efficient expansion of Epstein-Barr virus-specific CD4+ T cells by using virus-like particles, J Virol, vol.82, p.18272580, 2008.

S. Linnerbauer, U. Behrends, D. Adhikary, K. Witter, and G. W. Bornkamm, Virus and autoantigenspecific CD4+ T cells are key effectors in a SCID mouse model of EBV-associated post-transplant lymphoproliferative disorders, PLoS Pathog, vol.10, p.24853673, 2014.

K. N. Heller, C. Gurer, and C. Munz, Virus-specific CD4+ T cells: ready for direct attack, J Exp Med, vol.203, p.16549599, 2006.

J. Mautner and G. W. Bornkamm, The role of virus-specific CD4+ T cells in the control of Epstein-Barr virus infection, Eur J Cell Biol, vol.91, p.21458882, 2012.

V. Schneidt, M. Ilecka, P. Dreger, D. G. Van-zyl, and S. Fink, Antibodies conjugated with viral antigens elicit a cytotoxic T cell response against primary CLL ex vivo, Leukemia, 2018.

B. Neuhierl, R. Feederle, W. Hammerschmidt, and H. J. Delecluse, Glycoprotein gp110 of Epstein-Barr virus determines viral tropism and efficiency of infection, Proc Natl Acad Sci U S A, vol.99, p.12409611, 2002.

M. H. Tsai, A. Raykova, O. Klinke, K. Bernhardt, and K. Gartner, Spontaneous lytic replication and epitheliotropism define an Epstein-Barr virus strain found in carcinomas, Cell Rep, vol.5, p.24120866, 2013.

C. Gurer, T. Strowig, F. Brilot, M. Pack, and C. Trumpfheller, Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses, Blood, vol.112, p.18519810, 2008.

S. Nikiforow, K. Bottomly, and G. Miller, CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation, J Virol, vol.75, p.11264363, 2001.

L. Zaritskaya, M. R. Shurin, T. J. Sayers, and A. M. Malyguine, New flow cytometric assays for monitoring cell-mediated cytotoxicity, Expert Rev Vaccines, vol.9, p.20518716, 2010.

C. Munz, K. L. Bickham, M. Subklewe, M. L. Tsang, and A. Chahroudi, Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1, J Exp Med, vol.191, p.10811859, 2000.

K. Bickham, C. Munz, M. L. Tsang, M. Larsson, and J. F. Fonteneau, EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function, J Clin Invest, vol.107, p.11134187, 2001.

D. Adhikary, U. Behrends, A. Moosmann, K. Witter, and G. W. Bornkamm, Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins, J Exp Med, vol.203, p.16549597, 2006.

T. Strowig, C. Gurer, A. Ploss, Y. F. Liu, and F. Arrey, Priming of protective T cell responses against virus-induced tumors in mice with human immune system components, J Exp Med, vol.206, p.19487422, 2009.

S. G. Tangye and U. Palendira, Human immunity against EBV-lessons from the clinic, vol.214, p.28108590, 2017.

V. A. Pudney, A. M. Leese, A. B. Rickinson, and A. D. Hislop, CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells, J Exp Med, vol.201, p.15684323, 2005.

R. J. Abbott, L. L. Quinn, A. M. Leese, H. M. Scholes, and A. Pachnio, CD8+ T cell responses to lytic EBV infection: late antigen specificities as subdominant components of the total response, J Immunol, vol.191, p.24146041, 2013.

J. M. Brooks, H. M. Long, R. J. Tierney, C. Shannon-lowe, and A. M. Leese, Early T Cell Recognition of B Cells following Epstein-Barr Virus Infection: Identifying Potential Targets for Prophylactic Vaccination, PLoS Pathog, vol.12, p.27096949, 2016.

C. Forrest, A. D. Hislop, A. B. Rickinson, and J. Zuo, Proteome-wide analysis of CD8+ T cell responses to EBV reveals differences between primary and persistent infection, PLOS Pathogens, vol.14, p.30248160, 2018.

M. A. Epstein, A. J. Morgan, S. Finerty, B. J. Randle, and J. K. Kirkwood, Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine, Nature, vol.318, p.2999604, 1985.

J. G. Ogembo, M. R. Muraswki, L. W. Mcginnes, A. Parcharidou, and R. Sutiwisesak, A chimeric EBV gp350/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice, J Transl Med, vol.13, p.25885535, 2015.

D. A. Thorley-lawson and C. A. Poodry, Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo, J Virol, vol.43, p.6287039, 1982.

C. D. Shannon-lowe, B. Neuhierl, G. Baldwin, A. B. Rickinson, and H. J. Delecluse, Resting B cells as a transfer vehicle for Epstein-Barr virus infection of epithelial cells, Proc Natl Acad Sci U S A, vol.103, p.16606841, 2006.

H. Zhang, Y. Li, H. B. Wang, A. Zhang, and M. L. Chen, Ephrin receptor A2 is an epithelial cell receptor for Epstein-Barr virus entry, Nature Microbiology, vol.3, pp.164-171, 2018.

J. Chen and K. Sathiyamoorthy, Ephrin receptor A2 is a functional entry receptor for Epstein-Barr virus, Nature Microbiology, vol.3, p.29292384, 2018.

J. Snijder, M. S. Ortego, C. Weidle, A. B. Stuart, and M. D. Gray, An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus, Immunity, vol.48, p.29669253, 2018.

M. Khyatti, P. C. Patel, I. Stefanescu, and J. Menezes, Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBVspecific antibody-dependent cellular cytotoxicity, J Virol, vol.65, p.1846213, 1991.

J. Sashihara, P. D. Burbelo, B. Savoldo, T. C. Pierson, and J. I. Cohen, Human antibody titers to EpsteinBarr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assay, Virology, vol.391, p.19584018, 2009.

H. E. Heslop, How I treat EBV lymphoproliferation, Blood, vol.114, pp.4002-4008, 2009.

D. A. Thorley-lawson and A. Gross, Persistence of the Epstein-Barr virus and the origins of associated lymphomas, N Engl J Med, vol.350, p.15044644, 2004.

S. Gottschalk and C. M. Rooney, Adoptive T-Cell Immunotherapy, Curr Top Microbiol Immunol, vol.391, p.26428384, 2015.

A. Merlo, R. Turrini, R. Dolcetti, P. Zanovello, and A. Rosato, Immunotherapy for EBV-associated malignancies, Int J Hematol, vol.93, p.21336546, 2011.

C. M. Rooney, C. A. Smith, C. Y. Ng, S. K. Loftin, and J. W. Sixbey, Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients, Blood, vol.92, p.9716582, 1998.

M. Yajima, K. Imadome, A. Nakagawa, S. Watanabe, and K. Terashima, A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses, J Infect Dis, vol.198, p.18627269, 2008.

R. Feederle, O. Klinke, A. Kutikhin, R. Poirey, and M. H. Tsai, Epstein-Barr Virus: From the Detection of Sequence Polymorphisms to the Recognition of Viral Types, Curr Top Microbiol Immunol, vol.390, p.26424646, 2015.

A. Cirac, S. Stutzle, M. Dieckmeyer, D. Adhikary, and A. Moosmann, Epstein-Barr virus strain heterogeneity impairs human T-cell immunity, Cancer Immunology, Immunotherapy, vol.67, p.29374782, 2018.

J. Pulvertaft and . Burkitt's-tumour, AFRICAN LYMPHOMA). Lancet, vol.1, p.14086209, 1964.

F. L. Graham, J. Smiley, W. C. Russell, and R. Nairn, Characteristics of a human cell line transformed by DNA from human adenovirus type 5, J Gen Virol, vol.36, p.886304, 1977.

S. Warming, N. Costantino, D. L. Court, N. A. Jenkins, and N. G. Copeland, Simple and highly efficient BAC recombineering using galK selection, Nucleic Acids Res, vol.33, p.15731329, 2005.

H. J. Delecluse, T. Hilsendegen, D. Pich, R. Zeidler, and W. Hammerschmidt, Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells, Proc Natl Acad Sci U S A, vol.95, p.9653172, 1998.

A. Janz, M. Oezel, C. Kurzeder, J. Mautner, and D. Pich, Infectious Epstein-Barr virus lacking major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands, J Virol, vol.74, p.11024143, 2000.

X. Lin, M. H. Tsai, A. Shumilov, R. Poirey, and H. Bannert, The Epstein-Barr Virus BART miRNA Cluster of the M81 Strain Modulates Multiple Functions in Primary B Cells, PLoS Pathog, vol.11, p.26694854, 2015.